Literature DB >> 28861485

Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid.

John Merrick1, Brian Lane1, Terri Sebree2, Tony Yaksh3, Carol O'Neill2, Stan L Banks2.   

Abstract

Introduction: In recent research, orally administered cannabidiol (CBD) showed a relatively high incidence of somnolence in a pediatric population. Previous work has suggested that when CBD is exposed to an acidic environment, it degrades to Δ9-tetrahydrocannabinol (THC) and other psychoactive cannabinoids. To gain a better understanding of quantitative exposure, we completed an in vitro study by evaluating the formation of psychoactive cannabinoids when CBD is exposed to simulated gastric fluid (SGF).
Methods: Materials included synthetic CBD, Δ8-THC, and Δ9-THC. Linearity was demonstrated for each component over the concentration range used in this study. CBD was spiked into media containing 1% sodium dodecyl sulfate (SDS). Samples were analyzed using chromatography with UV and mass spectrometry detection. An assessment time of 3 h was chosen as representative of the maximal duration of exposure to gastric fluid.
Results: CBD in SGF with 1% SDS was degraded about 85% after 60 min and more than 98% at 120 min. The degradation followed first-order kinetics at a rate constant of -0.031 min-1 (R2=0.9933). The major products formed were Δ9-THC and Δ8-THC with less significant levels of other related cannabinoids. CBD in physiological buffer performed as a control did not convert to THC. Confirmation of THC formation was demonstrated by comparison of mass spectral analysis, mass identification, and retention time of Δ9-THC and Δ8-THC in the SGF samples against authentic reference standards. Conclusions: SGF converts CBD into the psychoactive components Δ9-THC and Δ8-THC. The first-order kinetics observed in this study allowed estimated levels to be calculated and indicated that the acidic environment during normal gastrointestinal transit can expose orally CBD-treated patients to levels of THC and other psychoactive cannabinoids that may exceed the threshold for a physiological response. Delivery methods that decrease the potential for formation of psychoactive cannabinoids should be explored.

Entities:  

Keywords:  THC; cannabidiol; degredation; drug discovery; gastric fluid; kinetics

Year:  2016        PMID: 28861485      PMCID: PMC5576596          DOI: 10.1089/can.2015.0004

Source DB:  PubMed          Journal:  Cannabis Cannabinoid Res        ISSN: 2378-8763


  25 in total

Review 1.  Is there any clinically relevant cannabinoid-induced analgesia?

Authors:  Birgit Kraft
Journal:  Pharmacology       Date:  2012       Impact factor: 2.547

Review 2.  Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

Authors:  Angelo A Izzo; Francesca Borrelli; Raffaele Capasso; Vincenzo Di Marzo; Raphael Mechoulam
Journal:  Trends Pharmacol Sci       Date:  2009-09-02       Impact factor: 14.819

Review 3.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 4.  Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results.

Authors:  Sunil K Aggarwal
Journal:  Clin J Pain       Date:  2013-02       Impact factor: 3.442

Review 5.  Cannabidiol as an emergent therapeutic strategy for lessening the impact of inflammation on oxidative stress.

Authors:  George W Booz
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

Review 6.  Human studies of cannabinoids and medicinal cannabis.

Authors:  P Robson
Journal:  Handb Exp Pharmacol       Date:  2005

7.  Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures.

Authors:  Nicholas A Jones; Sarah E Glyn; Satoshi Akiyama; Thomas D M Hill; Andrew J Hill; Samantha E Weston; Matthew D A Burnett; Yuki Yamasaki; Gary J Stephens; Benjamin J Whalley; Claire M Williams
Journal:  Seizure       Date:  2012-04-19       Impact factor: 3.184

8.  A prospective study of adverse drug reactions to antiepileptic drugs in children.

Authors:  Mark Anderson; Oluwaseun Egunsola; Janine Cherrill; Claire Millward; Apostolos Fakis; Imti Choonara
Journal:  BMJ Open       Date:  2015-06-01       Impact factor: 2.692

9.  Cannabidiol in humans-the quest for therapeutic targets.

Authors:  Simon Zhornitsky; Stéphane Potvin
Journal:  Pharmaceuticals (Basel)       Date:  2012-05-21

10.  The endocannabinoid system, cannabinoids, and pain.

Authors:  Perry G Fine; Mark J Rosenfeld
Journal:  Rambam Maimonides Med J       Date:  2013-10-29
View more
  24 in total

1.  Oral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans: A Pharmacokinetic Study in Healthy Subjects.

Authors:  José Alexandre S Crippa; Antonio Waldo Zuardi; Jaime Eduardo Cecílio Hallak; Bruna Miyazawa; Sandra Aparecido Bernardo; Carmem Maria Donaduzzi; Silvane Guzzi; Wagner Alex Jann Favreto; Alline Campos; Maria Eugênia C Queiroz; Francisco S Guimarães; Patrícia Moura da Rosa Zimmermann; Letícia Mello Rechia; Volnei Jose Tondo Filho; Liberato Brum Junior
Journal:  Cannabis Cannabinoid Res       Date:  2020-02-27

Review 2.  Cannabis for Pain and Headaches: Primer.

Authors:  Philip S Kim; Michael A Fishman
Journal:  Curr Pain Headache Rep       Date:  2017-04

3.  Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle.

Authors:  Gustavo Gonzalez-Cuevas; Remi Martin-Fardon; Tony M Kerr; David G Stouffer; Loren H Parsons; Dana C Hammell; Stan L Banks; Audra L Stinchcomb; Friedbert Weiss
Journal:  Neuropsychopharmacology       Date:  2018-03-22       Impact factor: 7.853

4.  Will tetrahydrocannabinol be formed from cannabidiol in gastric fluid? An in vivo experiment.

Authors:  Simon Franz; Josefine Herzog; Gisela Skopp; Frank Musshoff
Journal:  Int J Legal Med       Date:  2022-10-03       Impact factor: 2.791

5.  Orally administered cannabidiol does not produce false-positive tests for Δ9 -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.

Authors:  Danielle McCartney; Richard C Kevin; Anastasia S Suraev; Christopher Irwin; Ronald R Grunstein; Camilla M Hoyos; Iain S McGregor
Journal:  Drug Test Anal       Date:  2021-08-30       Impact factor: 3.234

Review 6.  The Essential Medicinal Chemistry of Cannabidiol (CBD).

Authors:  Kathryn M Nelson; Jonathan Bisson; Gurpreet Singh; James G Graham; Shao-Nong Chen; J Brent Friesen; Jayme L Dahlin; Matthias Niemitz; Michael A Walters; Guido F Pauli
Journal:  J Med Chem       Date:  2020-09-10       Impact factor: 7.446

7.  Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis.

Authors:  Tory R Spindle; Edward J Cone; David Kuntz; John M Mitchell; George E Bigelow; Ronald Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2020-03-07       Impact factor: 3.220

8.  Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration.

Authors:  Dennis J Sholler; Tory R Spindle; Edward J Cone; Elia Goffi; David Kuntz; John M Mitchell; Ruth E Winecker; George E Bigelow; Ronald R Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2022-05-20       Impact factor: 3.220

9.  Origin of Δ9-Tetrahydrocannabinol Impurity in Synthetic Cannabidiol.

Authors:  Cinzia Citti; Fabiana Russo; Pasquale Linciano; Sarah Sylvana Strallhofer; Francesco Tolomeo; Flavio Forni; Maria Angela Vandelli; Giuseppe Gigli; Giuseppe Cannazza
Journal:  Cannabis Cannabinoid Res       Date:  2021-02-12

10.  Kinetics of CBD, Δ9-THC Degradation and Cannabinol Formation in Cannabis Resin at Various Temperature and pH Conditions.

Authors:  Wuttichai Jaidee; Ittipon Siridechakorn; Siwames Nessopa; Vanuchawan Wisuitiprot; Nathareen Chaiwangrach; Kornkanok Ingkaninan; Neti Waranuch
Journal:  Cannabis Cannabinoid Res       Date:  2021-06-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.